Clinical and epidemiological characteristic of chronic hepatitis C in the republic of Tyva

Aim: To assess the current epidemiological situation and establish the dominant clinical profile of patients with chronic hepatitis C, taking into account the stage of the disease and the molecular genetic characteristics of the virus in the Republic of Tyva.  

Materials and methods: Based on the annual reports of the dispensary observation office of the Infectious Hospital of the Republic of Tyva, an electronic database was developed using the licensed Office Excel 2016 program, which included results on the health status of patients, clinical, laboratory and instrumental data, including molecular biological data with the determination of HCV genotypes. The analysis of the data of the state statistical reporting of infectious morbidity in the Russian Federation (form №2 “Information on infectious and parasitic diseases”) was carried out. Analytical tables developed by specialists of the Scientific and Methodological Center of the Saint-Petersburg Pasteur Institute for the period 2012-2022. The data of the Reference Center for Monitoring Viral Hepatitis of the Federal State Budgetary Institution “Central Research Institute of Epidemiology” of Rospotrebnadzor were used.  

Results. Over the past two years, the decrease in incidence in the Republic of Tyva is likely due to a decrease in the number of examinations, a decrease in patients seeking outpatient care, and insufficient screening in the context of the COVID-19 pandemic. Clinical, laboratory and instrumental examination of patients with HCV revealed the predominance of HCV-infected genotype 1 (49.4%), with F0-F2 fibrosis in 79% of cases. The clinical profile of typical patients with chronic hepatitis C was established; whose share in the total structure of the examined was 38.4%.  

Conclusion: There is a tendency to reduce the incidence of chronic hepatitis C in the Republic of Tyva. Based on the clinical information base, the most typical characteristics of chronic hepatitis C patients living in the Republic of Tyva have been established. 

1. Viral hepatitis in the Russian Federation: An analytical review / E. V. Esaulenko, L. V. Lyalina, A.V. Semenov [et al.]. – St. Petersburg: St. Petersburg Scientific Research Institute of Epidemiology and Microbiology named after Pasteur, 2018. – 112 p.

2. Electronic resource: WHO. Access mode: https://www. who.int/ru/news-room/fact-sheets/detail/hepatitis-c

3. Yushchuk N.D. The burden of mortality from viral hepatitis B and C: assessment methodology and indicators in Moscow in 2015-2017 / Zairatyants O.V., Znojko O.O., Khripun A.I., Dudina K.R., Gudkova S.B., Klimova E.A., Krasnenkova S.F., Zhuravleva A.V., Orekhov O.O., Bely P.A. // Infectious diseases: news, opinions, education. 2018. Vol. 7, No. 4. pp. 8-14.

4. Esaulenko E.V. Cirrhosis of the liver as an outcome of chronic hepatitis C / Sukhoruk A.A., Gerasimova O.A. // Journal of Infectology. 2014. Vol. 6. No. 1. pp. 67-71.

5. Ghany M.G. AASLD-IDSA. Hepatitis C guidance 2019 update / Morgan T.R. // J. Hepatology. 2020. Vol. 71, No. 2. pp. 686-721.

6. Esaulenko E. V. Hepatitis C in Russia and the North-Western Federal District: results of the first stage of the global infection elimination program / A. A. Dzemova, G. F. Trifonova [and others] // HIV infection and immunosuppression. – 2021. – Vol. 13. – No. 3. – pp. 40-51.

7. Chulanov V.P. Chronic hepatitis C as a problem of healthcare in Russia today and tomorrow / Pimenov N.N., Mamonova N.A., Sagalova O.I., Shestakova I.V., Pokrovsky V.I.// Therapeutic Archive. 2015. Vol. 7, No. 495. pp. 5-10.

8. Ivashkin V. T. Chronic viral hepatitis C: Clinical recommendations / V. T. Ivashkin, N. D. Yushchuk, P. O. Bogomolov [et al.]. – Moscow: Non-profit Partnership “National Scientific Society of Infectious Diseases”, 2021. – 71 p.

9. Mikhailov M.I. Draft program for the control and elimination of viral hepatitis as problems of public health in the Russian Federation / Yushchuk N.D., Malinnikova E.Yu., Kyuregyan K.K., Isaeva O.V., Znoko O.O., Klimova E.A. // Infectious diseases: news, opinions, training. 2018. vol. 7, No. 2. pp. 52-58.

10. Kravchenko I.E. The state of medical care for patients with chronic hepatitis C in the Russian Federation / Ginyatullin R.R., Amon E.P., Malinnikova E.Yu. // Infectious diseases: news, opinions, training. 2019. Vol. 8, No. 4. pp. 48-57.

11. Yushchuk N.D. Results of forecasting the epidemic situation for hepatitis C depending on the strategy of antiviral therapy / Ivakhnenko O.I., Znoko O.O., Dudina K.R., Zaratyants O.V., Mikhailov M.I., Malinnikova E.Yu., Krasnenkova S.F., Kyuregyan K.K., Kravchenko I.E., Sozinova Yu.M., Fazylov V.H., Sleptsova S.S., Isaeva O.V., Kichatova V.S., Lopatukhina M.A., Potemkin I.S., Krasnova O.G., Ivanov I.B., Rukosueva E.V. // Infectious diseases: news, opinions, training. 2020. Vol. 9, no. 4. pp. 60-71.

12. Durham D.P. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States // Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. Clin Infect Dis. 2016 Feb 1; 62(3):298-304.

13. Soboleva N. V. The prevalence of hepatitis C virus among the conditionally healthy population of the Russian Fed eration / A. A. Carlsen, T. V. Kozhanova [et al.] // Journal of Infectology. – 2017. – Vol. 9. – No. 2. – pp. 56-64.

14. Rasporyazhenie Pravitel’stva RF ot 2 noyabrya 2022 g. № 3306-r “On approval of the action plan to combat chronic viral hepatitis C in the territory of the Russian Federation in the period up to 2030”

15. Butskaya M. Yu. Modern epidemiological aspects of acute viral hepatitis in Russia / A.D. Bushmanova, E. N. Priyma [et al.] // Epidemiology and infectious diseases. – 2021. – Vol. 26. – No. 2. – pp. 67-74. – DOI 10.17816/EID105585.

16. Global Hepatitis Report 2017. Geneva: World Health Organization, 2017. https://apps.who.int/iris/bitstream/handle/10665/ 255016/9789241565455-eng.pdf;jsessionid=6872 60DEF2EE5404EEA21A9931153739?sequence=1 (succeeded 01.08.2021).

17. SanPiN 3.3686-21 “Sanitary and epidemiological requirements for the prevention of infectious diseases” VII. Prevention of viral hepatitis B and C (Registered with the Ministry of Justice of Russia on 02/15/2021 N 62500)

18. Blach S. Impact of COVID-19 on global HCV elimination efforts // Kondili L.A., Aghemo A., Cai Z., Dugan E., Estes C., Gamkrelidze I., Ma S., Pawlotsky JM., Razavi-Shearer D., Razavi H., Waked I., Zeuzem S., Craxi A.// J. Hepatology. 2021. Vol. 74, No. 1. pp. 31-36.

19. Wingrove C. The impact of COVID-19 on hepatitis elimination / Ferrier L., James C., Wang S. // The Lancet Gastroenterology & Hepatology. 2020. Vol. 5, No. 9. pp. 792-794.

20. Khorkova E. V. Topical issues of epidemiological surveillance of chronic viral hepatitis B, C, D and hepatocellular carcinoma at the regional level / L. V. Lyalina, O. M. Mikailova [et al.] // Public health and habitat – ZNiSO. – 2021. – Vol. 29. – No. 8. – pp. 76-84. – DOI 10.35627/2219-5238/2021-29- 8-76-84 .

21. State Report “On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2021” https://www.rospotrebnadzor.ru

22. Dzemova A.A. Dominant profile of patients with chronic hepatitis C in the modern period / Shibaeva E.O., Ganchenko R.A., Novak K.E. // In the collection: Socially significant and especially dangerous infectious diseases. Materials of the VIII All-Russian Interdisciplinary Scientific and Practical Conference with international participation. Sochi, 2021. pp. 48-50.